Analysts Issue Forecasts for Nektar Therapeutics’ FY2025 Earnings (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR – Get Rating) – Stock analysts at Zacks Research issued their FY2025 EPS estimates for Nektar Therapeutics in a research report issued to clients and investors on Tuesday, March 14th. Zacks Research analyst K. Shah expects that the biopharmaceutical company will earn ($1.01) per share for the year. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.89) per share.

Several other research analysts have also recently commented on NKTR. Oppenheimer reduced their target price on shares of Nektar Therapeutics from $5.00 to $3.00 and set a “market perform” rating for the company in a report on Monday, March 6th. Jefferies Financial Group cut shares of Nektar Therapeutics from a “hold” rating to an “underperform” rating and reduced their target price for the stock from $3.20 to $1.50 in a report on Friday, February 24th. SVB Leerink cut their price target on shares of Nektar Therapeutics from $5.00 to $3.00 and set a “market perform” rating for the company in a research note on Friday, February 24th. StockNews.com began coverage on shares of Nektar Therapeutics in a research note on Thursday. They issued a “hold” rating for the company. Finally, SVB Securities cut their price target on shares of Nektar Therapeutics from $5.00 to $3.00 in a research note on Friday, February 24th. Three analysts have rated the stock with a sell rating and four have given a hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.08.

Nektar Therapeutics Trading Down 12.5 %

Shares of NKTR opened at $0.98 on Friday. Nektar Therapeutics has a 12 month low of $0.96 and a 12 month high of $6.40. The firm has a fifty day simple moving average of $2.30 and a 200 day simple moving average of $2.93. The stock has a market capitalization of $185.47 million, a price-to-earnings ratio of -0.50 and a beta of 1.10.

Nektar Therapeutics (NASDAQ:NKTR – Get Rating) last issued its quarterly earnings data on Tuesday, February 28th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. Nektar Therapeutics had a negative net margin of 399.98% and a negative return on equity of 76.92%. The company had revenue of $22.02 million during the quarter, compared to the consensus estimate of $22.21 million. During the same quarter in the prior year, the firm earned ($0.79) earnings per share. The firm’s revenue was down 11.9% compared to the same quarter last year.

Insider Buying and Selling

In related news, CEO Howard W. Robin sold 19,635 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, February 16th. The shares were sold at an average price of $3.00, for a total transaction of $58,905.00. Following the sale, the chief executive officer now directly owns 960,158 shares in the company, valued at approximately $2,880,474. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Howard W. Robin sold 19,635 shares of the business’s stock in a transaction on Thursday, February 16th. The shares were sold at an average price of $3.00, for a total transaction of $58,905.00. Following the transaction, the chief executive officer now owns 960,158 shares in the company, valued at approximately $2,880,474. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jillian B. Thomsen sold 10,267 shares of the business’s stock in a transaction on Thursday, February 16th. The shares were sold at an average price of $3.00, for a total transaction of $30,801.00. Following the sale, the chief financial officer now owns 313,497 shares of the company’s stock, valued at approximately $940,491. The disclosure for this sale can be found here. Insiders have sold a total of 40,386 shares of company stock worth $121,158 in the last ninety days. Company insiders own 3.38% of the company’s stock.

Hedge Funds Weigh In On Nektar Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in NKTR. Amalgamated Bank lifted its holdings in Nektar Therapeutics by 3.6% during the third quarter. Amalgamated Bank now owns 83,139 shares of the biopharmaceutical company’s stock valued at $266,000 after purchasing an additional 2,909 shares during the last quarter. Texas Permanent School Fund lifted its holdings in shares of Nektar Therapeutics by 2.4% in the second quarter. Texas Permanent School Fund now owns 133,943 shares of the biopharmaceutical company’s stock worth $509,000 after buying an additional 3,101 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Nektar Therapeutics by 0.3% in the fourth quarter. Principal Financial Group Inc. now owns 1,177,797 shares of the biopharmaceutical company’s stock worth $2,662,000 after buying an additional 3,212 shares in the last quarter. Metropolitan Life Insurance Co NY increased its position in shares of Nektar Therapeutics by 43.7% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 11,340 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 3,450 shares during the last quarter. Finally, ProShare Advisors LLC increased its position in shares of Nektar Therapeutics by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 44,375 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 3,506 shares during the last quarter. 92.30% of the stock is owned by hedge funds and other institutional investors.

About Nektar Therapeutics

(Get Rating)

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases.